1973
DOI: 10.1001/archneur.1973.00490260043008
|View full text |Cite
|
Sign up to set email alerts
|

Etilefrine in the Treatment of Levodopa-Induced Orthostatic Hypotension

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
12
0

Year Published

1973
1973
2015
2015

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 20 publications
(13 citation statements)
references
References 15 publications
0
12
0
Order By: Relevance
“…Etilefrine (5–10 mg) was used in 15 PD patients to increase blood pressure upon standing (mean increase of 4.3%) reporting only headaches as adverse outcomes (Miller et al, 1973). …”
Section: Therapeutic Measuresmentioning
confidence: 99%
“…Etilefrine (5–10 mg) was used in 15 PD patients to increase blood pressure upon standing (mean increase of 4.3%) reporting only headaches as adverse outcomes (Miller et al, 1973). …”
Section: Therapeutic Measuresmentioning
confidence: 99%
“…Etilefrine hydrocholoride, a sympathomimetic drug which stimulates both a-and~-adrenergic receptors, stabilised the blood pressure in 14 of the 15 patients who developed orthostatic hypotension during levodopa therapy (Miller, 1973). No side-effects or abnormal laboratory findings were encountered.…”
Section: Cardiovascular Problemsmentioning
confidence: 95%
“…In symptomatic orthostatic hypotension, Lund et al [15] reported that in a group of 15 geriatric patients in which tachycardia was associated with orthostatic hyper tension, significant benefit was obtained following the administration of ENP. ENP also appears to be effective in orthostatic hypotension asso ciated withL-dopa administration [18].…”
Section: Sympathomimetic Aminesmentioning
confidence: 98%
“…An instance of special interest is the orthostatic hypotension which accom panies administration of L-dopa for Parkinson's disease [3,8,18,31]. The availability of peripheral dopa-decarboxylase inhibitors [21] makes it possible to correct this and other side effects of L-dopa administration while retaining the central effect of therapeutic benefit in Parkinson's disease.…”
Section: Introductionmentioning
confidence: 99%